Nuvation Bio Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held by Nuvation Bio Inc. on May 21, 2026. The meeting was conducted to vote on director elections, auditor ratification, and executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders representing 83.6% of Class A and 100% of Class B common stock voted on three proposals:
- Proposal 1 (Election of Directors): All nominees were elected. Robert B. Bazemore, Jr. received 197,674,280 votes FOR. Robert Mashal, M.D. received 216,772,840 votes FOR. Kim Blickenstaff (Class B Director) received 1,000,000 votes FOR.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of KPMG LLP for the fiscal year ending December 31, 2026. Votes cast were 290,273,104 FOR, 413,176 AGAINST, and 245,516 ABSTAIN.
- Proposal 3 (Executive Compensation): Stockholders approved the advisory compensation of named executive officers. Votes cast were 230,050,644 FOR, 4,950,024 AGAINST, and 328,694 ABSTAIN.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the definitive proxy statement filed on April 10, 2026, for detailed biographies of elected directors and executive compensation specifics.
- Confirm the total number of shares outstanding as of the March 25, 2026 record date to contextualize the 83.6% participation rate.
- Review the Company's most recent 10-K or 10-Q for financial performance data, as this 8-K contains no financial metrics.